DECOY THERAPEUTICS
Decoy Therapeutics is a preclinical stage biotech company building a pandemic preparedness drug development platform using AI design of peptide ‘decoys’ that directly interfere with viral replication machinery.
DECOY THERAPEUTICS
Industry:
Biotechnology Therapeutics
Founded:
2020-01-01
Status:
Active
Total Funding:
250 K USD
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Rain Therapeutics
Rain Therapeutics is a operator of a clinical stage biotechnology company.
Current Employees Featured
Founder
Investors List
Massachusetts Life Sciences Center
Massachusetts Life Sciences Center investment in Convertible Note - Decoy Therapeutics
More informations about "Decoy Therapeutics"
Decoy Therapeutics Inc. - LinkedIn
Decoy Therapeutics Inc. Biotechnology Research CAMBRIDGE, Massachusetts 455 followers We are engineering the next generation of peptide conjugate therapies to protect and expand …See details»
ListingTrack | Decoy Therapeutics, Inc.
Dive into the detailed profile of Decoy Therapeutics, Inc. . Explore its market performance, IPO details, and significant developments. Decoy Therapeutics is a preclinical-stage biotechnology …See details»
Decoy Therapeutics - PitchBook
Decoy Therapeutics General Information Description. Developer of an antiviral medicine designed to address future pandemics rapidly. The company leverages AI technology to develop an anti …See details»
Salarius Pharmaceuticals and Decoy Therapeutics Announce …
Jan 13, 2025 This proposed transaction is expected to facilitate multiple value-creating inflection points with Decoy’s pipeline of peptide conjugate therapeutics engineered by its IMP 3 ACT …See details»
Salarius Pharmaceuticals and Decoy Therapeutics …
Jan 13, 2025 Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence tools alongside high-speed synthesis techniques to rapidly design ...See details»
a991fs2022and2023 - SEC.gov
Notes to Consolidated Financial Statements December 31, 2023 and 2022 F-6 NOTE 1 – ORGANIZATION, BUSINESS AND BASIS OF PRESENTATION Decoy Therapeutics, Inc. …See details»
Decoy Therapeutics - Funding, Financials, Valuation & Investors
Organization. Decoy Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Funding Rounds 1. ... Decoy …See details»
Decoy Therapeutics Inc. | STEX - Startup
Jan 20, 2023 Decoy Therapeutics is engineering broad-acting antivirals that target the viruses of today and preemptively protect against the viruses of tomorrow. Description. Description. The …See details»
Salarius Pharmaceuticals and Decoy Therapeutics Announce …
Jan 13, 2025 © 2025 Salarius Pharmaceuticals, Inc. All Rights Reserved. Privacy and Terms of UseSee details»
Antiviral Drugs Offer Quick Defense Against Pandemics …
Jan 20, 2023 Decoy Therapeutics is developing a new class of protective antiviral drugs that can be optimized for emerging threats, manufactured surprisingly quickly and delivered as a nasal spray. The company recently …See details»
Decoy Therapeutics, Inc - Bill & Melinda Gates Foundation
Decoy Therapeutics, Inc Committed grants. More in this section Committed grants. Decoy Therapeutics, Inc Grantee website Cambridge, Massachusetts, United States Purpose. to …See details»
Decoy Therapeutics - VentureRadar
LBV takes a unique model focused on lean operations, smart capital allocation, and diversified yet complementary nexus of 7 companies developing 10 first-in-class therapeutics. RDP Pharma …See details»
Decoy Therapeutics - Creative Destruction Lab
Decoy Therapeutics (DecoyTx) is a pharmaceutical company commercializing its IMPACT platform, which designs and develops antiviral products that prevent viral infection. Decoy’s …See details»
Decoy Therapeutics Inc. Company Profile -Sales, Contacts, …
Decoy Therapeutics is in the Business Activities At Non-Commercial Site industry within the Business Services sector and has been in business for approximately 4 years. The Most …See details»
Diclofenac Sodium - Drug Targets, Indications, Patents - Synapse
3 days ago Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence tools alongside high-speed synthesis techniques to …See details»
Indaptus Therapeutics reports new data on Phase 1 trial of Decoy20
3 days ago Indaptus Therapeutics provided an update on key pharmacodynamic findings from the weekly dosing cohort of its ongoing Phase 1 trial of Decoy20.As announced in last week’s …See details»
Indaptus Therapeutics Says New Data on Decoy20 Shows Broad …
2 days ago Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Companyâ s approach is based on …See details»
Indaptus Therapeutics Reports New Data Demonstrating
2 days ago In pre-clinical studies tumor eradication was observed with Decoy product candidates in combination with anti-PD-1 checkpoint therapy, low-dose chemotherapy, a non …See details»
Indaptus Therapeutics Initiates Phase 1 Combination Study of …
5 days ago NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel …See details»
Indaptus Therapeutics Reports New Data Demonstrating …
2 days ago Decoy product candidates represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal …See details»